Ludvig from Sweden

Registered at the short selling broker Skilling, 3 minutes ago.

» Try Skilling you too
69% of retail CFD accounts lose money.
Don't show again

Sanofi (SNY) shares information

Sanofi


24h Change

-0.26 %

SNY

Live rate: Market closed

Stock data per Monday 19 Oct, 2020

SNY
NASDAQ
50.27
50.95
50.14
-0.13 (-0.26%)
US Market is closed

Live Stock price in graph for Sanofi (SNY)

  • Latest Volume

    788,183 (1.3 %)

  • Volume prev. day

    778,070

  • Avg. daily volume

    963,513

  • Market cap

    125,988,783,600

  • P/E ratio

    10.22

  • Today high

    51.01

  • Today low

    50.04

  • 52 week high

    55

  • 52 week low

    37.62

  • YTD Change

    n/a

Quick links

Broker recommendations for Sanofi

The Sanofi stock is rated at 1.391304 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Thursday 8 October, 2020 by a total of 23 brokers. This means that the consensus of the 23 different brokers is leaning toward to buy/moderate buy.

Sell
0 (0%)
Underweight
0 (0%)
Hold
8 (34.78%)
Overweight
2 (8.7%)
Buy
13 (56.52%)

Price target by analysts

The 20 latest analyst estimates, per Saturday 17 October, 2020, show the following high, low and average price targets.
Target Average: 61.78 USD
Target High: 69.15 USD
Target Low: 50.2 USD

 

Latest news about Sanofi

Below you can find the most recent news posts about Sanofi, primarily from US and UK based news sources.

Enoxaparin Sodium Market Inclined to Deliver Positive Growth Results until 2025 With Key Players| Sanofi, Sanodz, Themis Medicare Limited

Monday, 19 October 2020, 18:10:04
The research study covers the current scenario and growth prospects of the Enoxaparin Sodium market (2020-2025) according to the analysis . This study includes a extensive analysis of the key segments of the industry and also the regional analysis that
— OpenPR


Eczema Therapeutics Market 2020-28 advance research lead towards gigantic hike| Bausch Health Companies, Bayer AG, Eli Lilly, Encore Dermatology, LEO Pharma AS, Mylan NV, Pfizer, and Sanofi

Monday, 19 October 2020, 14:57:49
Eczema is a term for a group of conditions that make your skin inflamed or irritated. The most common type is atopic dermatitis or atopic eczema. “Atopic” refers to a person’s tendency to get allergic conditions such as asthma and
— OpenPR


COVID-19 tracker: J&J, BMS and AbbVie drugs pegged for NIH trial; Russia greenlights remdesivir to treat COVID-19

Friday, 16 October 2020, 21:30:00
The NIH picked drugs from J&J, BMS and AbbVie for a phase 3 trial in hospitalized patients. Russia approved remdesivir to treat COVID-19. Sanofi’s partnership exec isn’t sweating the lack of in-person meetings during the pandemic. Beckman Coulter is developing a childhood COVID-19 test, and Cue Health won a DOD contract to scale diagnostic production.
— FiercePharma


Sanofi’s mRNA Vaccine for Coronavirus to Enter Clinical Stage

Friday, 16 October 2020, 19:01:05
Sanofi (SNY) and Translate Bio select coronavirus vaccine candidate MRT5500 for clinical development, based on its promising pre-clinical data. A clinical study is anticipated by this year-end.
— Yahoo Finance


Rotavirus Prophylaxis Market Current and Future Trend Scenario Explored In New Latest Research Report| Merck & Co., Inc., Bharat Biotech, GlaxoSmithKline plc, Sanofi, Lanzhou Institute of Biologicals Products Co., Ltd

Friday, 16 October 2020, 15:40:20
The company profiles of all the major market players and brands that are dominating the Rotavirus Prophylaxis Market with moves like product launches, joint ventures, merges and accusations which in turn is affecting the sales, import, export, revenue and CAGR
— OpenPR


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €/$ 20
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have SNY available or trade one of the many other CFD stocks they have.
Risk warning: 75% of retail investor accounts lose money when trading CFDs with Capital.